Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...
With the expansion of the clinical development program, the companies plan to initiate pivotal studies of epacadostat in combination with KEYTRUDA in four additional tumors: non-small cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback